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 Introduction 
The treatment outcome in adult acute lymphoblastic leukemia (ALL) has 
lagged behind that in childhood ALL, for which a long-term survival of well over 
80% has been achieved. Adult ALL has a poor prognosis, with a 5-year overall 
survival (OS) rate of 39–50% despite aggressive chemotherapy [1–3] and only 
15% for patients over 50 years of age [3]. As the high incidence of relapse is a 
main cause of treatment failure in adult ALL, optimal post-remission therapy, 
particularly the efficacy of allogeneic hematopoietic stem cell transplantation 
(alloHCT), is a critical issue [4–6]. According to the International ALL Trial 
(MRC UKALL XII/ECOG E2993) of chemotherapy versus autologous and 
allogeneic transplantation, alloHCT confers the greatest durable benefit for 
standard-risk adult patients and is more effective than either chemotherapy or 
autologous transplantation [7]. AlloHCT in first complete remission (CR1) has 
generally been reserved for those patients who present with poor risk features. In 
several phase II studies, patients with high-risk disease treated with alloHCT 
displayed a disease-free survival (DFS) longer than would have been predicted, 
particularly those with Philadelphia chromosome positive (Ph+) ALL [4–6]. 
However, AlloHCT is associated with significant morbidity and mortality because 
of the toxicity of the conditioning regimen, graft-versus-host disease (GVHD), 
and the immune deficiency state that accompanies the procedure. These risks are 
significantly increased with advanced age and concurrent medical problems, 
limiting myeloablative (MA) transplantation to younger patients in good medical 
condition. 
Reduced-intensity conditioning allogeneic stem cell transplantation (RIC-
SCT) is a potential therapeutic approach for adults with high-risk ALL in 
remission who are ineligible for MA transplantation. This strategy decreases the 
risk of non-relapse mortality (NRM) while preserving the graft-versus-leukemic 
(GVL) effect. However, few studies have been conducted in patients with ALL, 
and all are retrospective [8–15]. Additionally, an evaluation of outcomes suggests 
that the GVL effect is more effective against myeloid malignancies such as acute 
and chronic myeloid leukemia, as well as malignancies of mature B cells such as 
low-grade non-Hodgkin’s lymphoma and multiple myeloma, but less so with a 
more undifferentiated B-cell disease such as pre-B ALL, particularly if not in 
remission [11,12]. Nevertheless, a few small studies have been reported to suggest 
that a role may well exist for RIC even in ALL. A retrospective analysis from the 
European Group for Blood and Marrow transplantation (EBMT) reported the 
outcome of 97 patients with ALL who received RIC and suggested that RIC may 
be effective in CR1 (2-year OS, 59%; treatment-related mortality (TRM), 18%) 
[15]. Considering the progress in adult ALL therapy and despite better disease 
control, high toxicity, and limited improvement in DFS in older adult patients, a 
detailed analysis is needed to determine whether RIC can improve the cure rate of 
older adults with ALL. Thus, we have conducted a direct comparison of the 
clinical outcomes of RIC and MA transplants in the treatment of patients 
exhibiting adult ALL.  
 Patients and methods 
Patients 
Between December 2001 and July 2009, a retrospective analysis was 
conducted on 49 ALL patients who received RIC (n = 14) and MA (n = 35) 
transplants at the Division of Hematology, the Yonsei University College of 
Medicine.  
Conditioning regimen and GVHD prophylaxis 
Transplantation procedures are shown in Table 3. Preparatory regimens 
included the following: in the RIC group, fludarabine (Flu)/busulfan (Bu) with (n 
= 3) or without (n =6) alemtuzumab, Flu/Bu with rabbit anti-thymocyte globulin 
(ATG) (n = 1), Flu/Bu with rituximab (n = 1), and Flu/melphalan (Mel) with (n = 
2) or without (n = 1) another Flu-based regimen. In the MA group, 25 patients 
received total body irradiation (TBI) at 8 Gy and cyclophosphamide (Cy) with (n 
= 1) or without ATG (n = 24), and 10 patients received Bu/Cy. For GVHD 
prophylaxis, all patients who received cyclosporine (CSP) received transplants 
from unrelated donors or tacrolimus from related donors with a short course of 
intravenous bolus methotrexate as a post-transplantation immunosuppressant.  
Definitions 
The diagnosis of GVHD was based on clinical evidence with histologic 
confirmation whenever possible. Acute GVHD was graded from 0 to IV and was 
defined and classified according to the modified Glucksberg grading system [16]. 
Additionally, chronic GVHD was defined and classified according to the Seattle 
criteria [17]. Neutrophil engraftment was defined as having an absolute neutrophil 
count exceeding 0.5 × 10
9
/L on the first of 3 consecutive days. Platelet 
engraftment was defined as having a platelet count of >20 × 10
9
/L on the first 7 
consecutive days without transfusion support. TRM was defined as death without 
progression of underlying disease. OS was defined as the duration of survival 
between transplant and either death or last follow up. DFS was defined as the 
duration of survival after transplant without disease progression, relapse, or death. 
When ALL recurred before engraftment, the underlying disease was considered to 
have progressed on the day of transplant.  
Statistical analyses 
Patient characteristics in the RIC and MA groups were compared using 
Pearson’s chi-squared test for discrete variables or the t-test for continuous 
variables. OS and DFS were the main end points of the present study. OS and 
DFS curves were constructed using Kaplan–Meier product-limit estimates [18]. 
Survival curves were compared using the log-rank test, taking the censored data 
into account. The list of features included was determined from a literature review 
that identified factors found to be associated with survival in patients treated with 
allogeneic transplantation. Factors associated by univariate analyses were 
subjected to multivariate analysis using backward stepwise proportional-hazard 
modeling. Values of p < 0.05 were considered to be statistically significant. 
 Statistical analyses were performed using SPSS 12.0 software (SPSS, Chicago, IL, 
USA). 
 
Results 
Patient characteristics  
The main clinical and biological characteristics at the time of diagnosis are 
displayed in Table 1. The median ages of the RIC and MA groups were 29 (range, 
15–56 years) and 30 years (range, 15–46 years), respectively (p = 0.646). The 
median intervals between the diagnosis and transplantation of the RIC and MA 
groups were 164.5 (range, 76–565 days) and 156 days (range, 70~971 days), (p = 
0.372). Twenty-three percent of patients in the RIC group required >28 days to 
achieve remission from the start of induction chemotherapy compared with 54.3% 
in the MA group (p = 0.054). Thirty-eight percent of patients in the RIC group 
had been diagnosed with high white blood cell (WBC) count (≥30 × 109/L for B-
precursor ALL and ≥100 × 109/L for T-precursor ALL) compared with 14.3% in 
the MA patient group (p = 0.067). Seven patients (50%) in the RIC group and 13 
(37.1%) in the MA group demonstrated cytogenetic high-risk factors, including 
being Ph+ (p = 0.165) and Ph (four patients in the RIC group and 13 in the MA 
group, p = 0.573). All patients who were diagnosed as being Ph+ received 
remission induction chemotherapy with imatinib mesylate (Glivec
®
). The 
incidence of T-cell lineage and biphenotypic ALL in the RIC group (four patients 
(28.5%)) was not significantly different compared with the MA group (three 
patients (8.6%); p = 0.209).  
Transplant procedures 
Clinical and biological features presenting at transplantation are summarized 
in Table 2. Thirty-four patients (69.4%) were transplanted in CR1, seven (14.2%) 
in second complete remission (CR2), and eight (16.4%) in third complete 
remission (CR3) or beyond. The status at transplantation was not different 
between the RIC and MA groups (p = 0.824). All donor–recipient pairs were 
human leukocyte antigen (HLA) typed using high-resolution genotyping for both 
HLA class I (HLA-A, -B, and -C) and II (HLA-DRB1) antigens. In total, 12 
patients (85.7%) in the RIC group and 33 (94.3%) in the MA group had full-
matched sibling or unrelated donors, and the remaining two in each group (14.3% 
and 5.7%, respectively) were transplanted from ≥1-allele mismatched donors (p = 
0.327). The median cell dose infused for the RIC and MA groups were 8.54 × 10
6
 
CD34+ cells/kg (range, 2.57–18.6 × 106 cells/kg) or 13.1 × 108 marrow-nucleated 
cells/kg (range, 3.58–18.26 × 108 cells/kg) and 6 × 106 CD34+ cells/Kg (range, 
1.74–27.52 × 106 cells/kg) or 6.8 × 108 marrow-nucleated cells/kg (range, 1.32–
14.8 × 10
8
 cells/kg), respectively. In the RIC group, the stem cell source was 
peripheral blood in 13 patients (92.9%) and bone marrow in one patient (7.1%) 
compared with 25 patients (71.4%) and 10 patients (28.6%) in the MA group, 
respectively (p = 0.108). 
 
 Engraftment 
All patients in the RIC and MA groups achieved neutrophil engraftment 
within a median interval of 13 days (range, 6–22 days) and 13 days (range, 4–23 
days; p = 0.906), respectively. The time required to achieve platelet engraftment 
was 11 days (median; range, 0–17 days; two patients never experienced 
thrombocytopenia) in the RIC group compared with 12 days (median; range 3–33 
days) in the MA group (p = 0.496). 
Graft-versus-host disease 
The incidences of grade II to IV acute GVHD (aGVHD) in the RIC and MA 
groups were comparable at 15.4% versus 25.7%, respectively (p = 0.101). The 
maximum ratings were grade II (n = 11), III (n = 13), or IV (n = 4). Additionally, 
the incidence of chronic GVHD (cGVHD) in patients who survived >100 days 
after transplantation was not significantly different between groups (45.7% versus 
40%, respectively; p = 0.783).  
Toxicities 
Two patients in the MA group died because of severe hepatic veno-occlusive 
disease (VOD). However, in the RIC group, hepatic VOD did not occur (p = 0.50). 
Infection developed in seven (50%) patients in the RIC group and 27 (77.1%) 
patients in the MA group; this difference was not significant (p = 0.065). The 
frequencies of cytomegalovirus disease, fungal infection, and acute renal failure 
were similar in both groups (p = 0.909, p = 0.375, and p = 0.150, respectively) 
(Table 4). 
Response to transplant 
In all patients, minimal residual disease (MRD) was monitored using 
polymerase chain reaction (PCR) for short tandem repeats (STR) or variable 
number tandem repeats (VNTR) at day 14 or 21 following HCT (first chimerism). 
Subsequently, results were collected at day 28, month 3, and month 9 after HCT. 
At the first evaluation, 13 patients in the RIC group had achieved complete donor 
chimerism compared with 44 in the MA group (p = 0.512). Relapses were 
observed in 10 of 14 patients in the RIC group (nine (64.2%), complete 
chimerism; one (7.1%), mixed chimerism) and in 44 of 45 patients in the MA 
group (12 (34.3%), complete chimerism; p = 0.055).  
Clinical outcomes  
In the RIC group, the 1-year NRM and relapse rates were 0% (p = 0.125) and 
64.3% (p = 0.055), respectively, compared with 34.8% and 34.3%, respectively, 
in the MA group. Although they were not statistically significant, we noted a 
trend toward higher NRM rates and lower relapse rates for the MA group. The 
most frequently encountered cause of NRM was infection, followed by GVHD. 
Relapse and death events were reported as days post HCT. The 3-year OS in the 
RIC and MA groups were 52% and 33%, respectively (Figure 1a; p = 0.280). The 
median duration of OS was 43.8 months (range, 43–44.3 months) in the RIC 
group and 55 months (range, 42–67.8 months) in the MA group. A significant 
difference in DFS was observed between the RIC and MA groups (Figure 1b). 
 The 3-year DFS rates were 25% in the RIC group and 68% in the MA group (p = 
0.001). Univariate analysis for OS and DFS was conducted using the following 
factors: conditioning regimen, age, donor type, the interval from diagnosis to 
transplantation, disease status at transplantation, and karyotype at diagnosis 
(Table 5). Age, donor type, and the interval from diagnosis to transplantation were 
statistically significant with respect to OS (p < 0.05); however, none of these 
factors was found to significantly influence DFS. In our multivariate analysis 
using Cox regression hazard models, none of the factors used in the multivariate 
analyses had any significant influence on OS and DFS.  
We divided patients into two age groups: ≤30 years and >30 years. 
According to Figure 2, OS was not significantly different between the RIC and 
MA groups for all patients (for patients ≤30 years old, 3-year OS = 59% vs. 78%, 
respectively (p = 0.892); for patients >30 years old, 3-year OS = 34% vs. 50%, 
respectively (p = 0.18)). However, the DFS in patients ≤30 years old in the MA 
group was superior to that in the RIC group (2-year DFS, 74% vs. 18%, 
respectively; p = 0.01). Conversely, the DFSs in the RIC and MA patient groups 
aged >30 years were 30% and 57%, respectively. No statistically significant 
difference was noted (p = 0.170; Figure 3). 
 
Discussion 
The rationale for RIC-SCT is that the toxicity of the conditioning regimen 
has been virtually removed, and the technique relies almost entirely on handling 
the GVL effect. The procedure is becoming established in acute myeloid leukemia 
(AML), multiple myeloma, and low-grade lymphoma [19]. Until now, few studies 
were conducted to evaluate the role of RIC-SCT in adult ALL [11–13]. ALL is 
relatively rare in adults, and its incidence increases dramatically with age. The 
cumulative incidence of ALL cases (per 100,000 in age-matched populations) 
triples in the >50-year-old age group compared with the 25- to 49-year-old age 
group [20]. Older patients have a very poor prognosis without HCT, but are 
generally ineligible for MA HCT because of high NRM, as demonstrated in the 
International ALL Trial [7]. The recently reported International ALL Trial 
comparing chemotherapy and allogeneic and autologous transplantation showed 
that alloHCT resulted in improved disease control in all adult patients with ALL, 
but with long-term benefit observed mostly in younger patients with lower-risk 
disease. Although the study clearly demonstrated better disease control, the 
overall benefit was undermined by the toxicity observed in older patients treated 
with the fully ablative TBI/etoposide regimen. Additionally, Larson [21] 
evaluated the outcomes for comparing chemotherapy with HCT. This trial has led 
to advocating early transplantation for nearly all patients, while others have 
cautioned a continued individual assessment. All agree that new approaches to 
reducing the toxicity of treatment in older patients are necessary. The 
development of RIC for ALL would give older patients transplant options and 
hope for disease control with fewer complications. Several studies have attempted 
to assess the efficacy of RIC-SCT for treatment of ALL in older patients. 
 In the present study, we compared the outcomes of 14 RIC with those of 35 
MA transplants, all of which were conducted at a single institution during the 
same time span. No statistically significant difference was observed by age, sex, 
presenting WBC count, ALL type (B-lineage, T-lineage, or biphenotype), 
cytogenetic abnormalities, extramedullary involvement at presentation, and 
delayed time to CR achievement (time to first CR >28 days from the start of 
induction chemotherapy). Chimerism analysis is mandatory after RIC regimens 
for alloHSCT because the kinetics of lymphoid and myeloid engraftment may 
differ from those observed after traditional MA conditioning. In the present study, 
we analyzed chimerism at day 14 or 21 following HCT (first chimerism). 
Subsequently, results were collected at day 28, month 3, and month 9 after HCT. 
In the RIC and MA groups, most patients (n = 13 vs. n = 44, respectively) 
achieved complete chimerism at day 14 or day 21, respectively, with no 
significant difference between the groups (p = 0.055). Our data show that the OS 
of the RIC and MA groups at all ages was not different (p = 0.280), but the DFS 
between the two groups at all ages was statistically significant (3-year DFS rates, 
25% vs. 68%, respectively; p = 0.001). We divided patients into two age groups: 
≤30 years and >30 years. At younger ages (≤30 years) in the RIC and MA groups, 
the OS and DFS demonstrated similar trends compared with those at all ages (3-
year OS, 59% vs. 78%, respectively; p = 0.892; 2-year DFS, 74% vs. 18%, 
respectively; p = 0.01). However, at older ages (>30 years), both the DFS and OS 
were not significantly different between the RIC and MA groups (30% vs. 57%, 
respectively; p = 0.170). Our data support recent reports that have compared the 
outcomes of RIC and MA transplants and have obtained results that generally 
favor RIC [22–24]. As anticipated, RIC with fludarabine-containing regimens was 
associated with a lower NRM than that observed after MA conditioning [25]. In 
our study, the 1-year NRM in the RIC group was 0%, compared with 34.8% in the 
MA group. Although it was not statistically significant (p = 0.125), we noted a 
trend toward higher NRM rates for the MA group. The development and severity 
of GVHD have been correlated with cytotoxic tissue injury and the resultant 
inflammatory cytokine milieu [26]. In our study, the incidence of both aGVHD 
(grade ≥II) and cGVHD (extensive) in the MA group (42.9% and 40%, 
respectively) was comparable to that in the RIC group (15.4% and 35.7%, 
respectively; p = 0.101 and p = 0.783, respectively). The low response rate in 
patients with ALL following donor leukocyte infusion (DLI) to treat post-
transplant relapse has led to questions about the contribution of the GVL effect in 
preventing relapse in this disease. The GVL effect is derived from observations of 
a higher relapse rate after autologous or syngeneic HCT compared with alloHCT, 
lower incidence of relapse in patients who had GVHD, and increased relapse rate 
in recipients of T-cell-depleted marrow grafts. The most compelling argument for 
a strong GVL effect in ALL comes from both single-institution and registry data 
[30]. The occurrence of acute, chronic, or both forms of GVHD correlated with 
the best DFS. A study of 192 patients with ALL, most of whom were transplanted 
in second remission, showed a consistent decrease in relapse rates in patients who 
 develop aGVHD (grade ≥II) and cGVHD compared with patients who do not 
develop aGVHD and cGVHD [5]. Table 6 shows the relapse rate after HCT and 
its correlation with aGVHD (p = 0.021) and cGVHD (p = 0.026). Most, but not all, 
reports of infectious complications after RIC-SCT have demonstrated a lower 
incidence of bacterial infections after transplantation but a persistent risk of 
invasive fungal and cytomegalovirus (CMV) infections [26–28]. According to our 
results, incidences of bacterial infection and CMV infection were similar between 
the RIC and MA groups (p = 0.065 and p = 0.909, respectively). In other studies, 
patients who received RIC experienced less hepatic toxicity.This underscores the 
deleterious effects of cellular cytotoxicity and release of proinflammatory 
cytokines on hepatocytes caused by ablative regimens [29]. Similar results were 
reported in our study. No patient in the RIC group experienced hepatic VOD, in 
contrast to three patients in the MA group.  
In conclusion, the present study suggests that RIC-SCT is a potential 
therapeutic approach for older patients (>30 years old) and those ineligible for 
MA transplantation, although all patients who experienced MA HCT demonstrate 
more favorable outcomes than those who experienced RIC. The poor outcome of 
older patients with ALL using either standard chemotherapy or transplant makes 
this an important consideration for treatment in those patients. However, the 
present study possesses several limitations because it was a retrospective study 
and its sample size was small. Thus, to validate these findings and those of other 
studies, we need to conduct a large, prospective clinical trial of RIC-SCT in 
patients with adult ALL, which will be the basis for prospective trials to determine 
whether RIC can improve the cure rate of older adults with ALL.
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 Abstract 
 
 
Allogeneic stem cell transplantation for patients with acute 
lymphoblastic leukemia: comparison of reduced-intensity 
conditioning versus myeloablative conditioning 
 
 
Allogeneic stem cell transplantation (SCT) is a curative treatment option for acute 
lymphoblastic leukemia (ALL). However, myeloablative (MA) SCT involves 
considerable toxicity, particularly in elderly patients, graft–versus-host disease 
(GVHD), and the immune deficiency state that accompanies the procedure. 
Reduced-intensity conditioning allogeneic stem cell transplantation (RIST) is 
being used for patients who are not able to endure MA conditioning because of 
the advanced age or other medical conditions. Also, RIST depends on graft-
versus-tumor effects for their eradication of malignant cells. There have been 
fewer studies conducted in patients with ALL, and all are retrospective. In 
addition, an evaluation of outcomes suggests that the GVL effect is more effective 
against myeloid malignancies, such as acute and chronic myeloid leukemia, and 
malignancies of mature B cells, such as low-grade non-Hodgkin`s lymphoma and 
multiple myeloma, but less so with a more undifferentiated B-cell disease, such as 
pre-B ALL, especially if not in remission. 
Nevertheless, a few small studies have been reported that suggested that there 
may well be a role for RIC-SCT even in ALL. Considering the progress in adult 
ALL therapy and despite better disease control, high toxicity and limited 
improvement in DFS in older adult patients, a detailed analysis is needed to 
determine if RIC can improve outcome of older adults with ALL. Therefore, we 
have conducted a direct comparison of the outcomes of RIC-SCT and 
myeloablative SCT in the treatment of patients exhibiting adults ALL. 
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Acute lymphoblastic leukemia, Allogeneic stem cell transplantation, Reduced-
intensity conditioning, Myeloablative conditioning 
 Table 1. Clinical and biological characteristics of patients at diagnosis 
 Reduced intensity (n = 14) Myeloablative (n = 35) p-value 
Male : Female 9 : 5 20 : 15 0.646 
Median age (range, year) 30 (12–56) 29 (15–46) 0.071 
High WBC count (%)
a
 5 (38.5) 5 (14.3) 0.067 
Immunophenotype (%)    
T-lineage 
B-lineage 
Biphenotype 
3 (21.4) 
10 (71.4) 
1 (7.1) 
1 (2.9) 0.209 
32 (91.4) 
2 (5.7) 
 
Cytogenetics (%)    
Adverse
c
 
Normal 
Other 
7 (50) 
6 (42.9) 
1 (7.1) 
13 (37.1) 0.692 
22 (62.9)  
4 (11.4)  
EM involvement (%) 4 (28.6) 4 (11.4) 0.147 
Delayed time to CR (%)
b
 3 (23.1) 19 (54.3) 0.054 
Abbreviations: WBC, white blood cell; EM, extramedullary; CR, complete remission. 
a Presenting WBC counts ≥30 × 109/L for B-precursor ALL and ≥100 × 109/L for T-precursor ALL. 
b Time to first CR >28 days from the start of induction chemotherapy.  
c Included t (9;22), t (4;11), t (8;14), low hypodiploidy/near triploidy, and complex karyotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Patient characteristics at transplantation 
 Reduced intensity Myeloablative p-value 
Disease status at HCT (%)    
CR1 9 (64.3) 25 (71.4) 0.824 
CR2
 
 2 (14.3) 5 (14.3)  
Other 3 (21.4) 5 (14.3)  
HLA     
Matched  12 (85.7) 33 (94.3) 0.327 
Mismatched 2 (14.3) 2 (5.7)  
ABO     
Matched 
Mismatched 
9 (64.3) 
5 (35.7) 
23 (65.7) 
12 (34.3) 
0.925 
 
Relation with donor    
Related 6 (42.9) 19 (54.3) 0.470 
Unrelated 8 (57.1) 16 (45.7)  
Stem cell source    
PB 13 (92.9) 25 (71.4) 0.108 
BM  1 (7.1) 10 (28.6)  
CMV serotype 
(donor to recipient) 
   
Pos to Pos 
Pos to Neg 
12 (85.7) 
2 (14.3) 
33 (94.3) 
2 (5.7) 
0.327 
 
Median CD34+ cells  
(× 10
6
/kg, median, range) 
8.5 (2.5~18.6) 6.5 (1.7~27.5) 0.514 
Total nucleated cells 
(× 10
8
/kg, median, range) 
13.1 (3.5~18.2) 6.8 (1.3~14.8) 0.868 
Neutrophil engraftment  
(days, median, range)
b
 
13 (6~22) 13 (4–23) 0.906 
Platelet engraftment  
(days, median, range)
b
 
11 (0~17) 12 (3~33) 0.496 
Abbreviations: HCT, hematopoietic stem cell transplantation; CR1, first complete remission; CR2, 
second complete remission; HLA, human leukocyte antigen; PB, peripheral blood; BM, bone 
marrow; CMV, cytomegalovirus; Neg, negative; Pos, positive.  
a
 Interval from the start of induction chemotherapy to the date of transplantation. 
b
 Neutrophil >5 × 10
9
/L, platelet >20 × 10
9
/L. 
 Table 3. Conditioning regimens  
Conditioning regimen 
No. of 
patients 
Reduced intensity 14 
Fludarabine (30 mg/m
2
/day I.V. for 30 min; D-7 to D-3) + Busulfan (3.2 mg/kg/day 
I.V. for 30 min; D-5 to D-2) 
11 
Fludarabine (25 mg/m
2
/day I.V. for 30 min; D-6 to D-3) + Melphalan (70 mg/kg/day 
I.V. for 30 min; D-3 to D-2) 
3 
Myeloablative 35 
TBI (8 Gy for D-8 to D-5) + Cyclophosphamide (60 mg/kg/day I.V. for 1 hr, D-3 to 
D-2) 
24 
Busulphan (3.2 mg/kg/day I.V. for 2 h, D-7 to D-4) + Cyclophosphamide (60 
mg/kg/day I.V. for 1 h, D-3 to D-2) 
10 
Abbreviations: I.V., intravenous; TBI, total body irradiation. 
 
Table 4. Toxicity and complication profile of the patients 
Abbreviations: GVHD, graft-versus-host disease; VOD, veno-occlusive disease; CMV, cytomegalovirus; 
TRM, treatment-related mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 Reduced intensity Myeloablative p-value 
Acute GVHD (grade ≥II) 2 (15.4) 9 (42.9) 0.101 
Chronic GVHD (extended) 5 (35.7) 14 (40) 0.783 
Hepatic VOD 0 3 (8.6) 0.263 
Infection 7 (50) 27 (77.1) 0.065 
CMV disease 3 (14.3) 7 (20) 0.909 
 3 (21.4) 13 (37.1) 0.294 
Causes of death 
Relapse/disease progression 
Infection 
GVHD 
Other TRM 
 
4 (28.6) 
5 (35.7) 
2 (14.3) 
0  
 
2 (5.7) 
9 (25.7) 
4 (11.4) 
5 (14.3) 
0.895 
 Table 5. Univariate proportional hazard analysis on OS and DFS 
 
OS DFS 
p-value p-value 
Age (≤30 vs. >30 years) 0.039 0.135 
Karyotype (adverse vs. other) 0.900 0.170 
Conditioning (RIC vs. MA) 0.157 0.263 
Donor type  
(related vs. unrelated) 
(matched vs. mismatched) 
 
0.046 
0.045 
 
0.082 
0.789 
Interval from Dx to HCT 
(<1 vs. ≥1 year) 
 
0.198 
 
0.412 
Disease status at transplant 
(CR1 vs. other) 
 
0.010 
 
0.201 
Abbreviations: RIC, reduced-intensity conditioning, MA, myeloablative; Dx, diagnosis; HCT, hematopoietic 
stem cell transplantation; CR1, first complete remission; OS, overall survival; DFS, disease-free survival. 
 
Table 6. Relapse after transplantation  
 
No. of relapsed 
patients (%) 
No. of non-relapsed 
patients (%) 
p-value 
Acute GVHD (grade ≥II) 8 (28.6) 13 (61.9) 0.021 
Chronic GVHD (extended) 6 (26.1) 15 (57.7) 0.026 
Abbreviations: GVHD, graft-versus-host disease.  
 
 
 
 
 
 
 
 
 
  
Fig. 1. Overall survival (a) and disease-free survival (b) in all patients 
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Fig. 2. Overall survival (a) and disease-free survival (b) in patients ≤30 years old 
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Fig. 3. Overall survival (a) and disease-free survival b) in patients >30 years old 
 
 
 
 
 
 
 
 
 
 
 
0.00 10000.00 20000.00 30000.00 40000.00
Days after transplantation
0.0
0.2
0.4
0.6
0.8
1.0
D
is
e
a
s
e
-
fr
e
e
 s
u
rv
iv
a
l
MA group
RIC group
p=0.170
생존함수
